New Zealand's medicines regulator, Medsafe, approved two psychiatrists on September 4, 2026, to prescribe pharmaceutical-grade MDMA to patients with severe post-traumatic stress disorder

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Trauma-informed support approaches aim to provide effective support for affected individuals by accounting for how past adversity impacts ongoing service interaction and behavior.

Preventing childhood adversity can be achieved by supporting parents, building life skills, challenging harmful social norms, and addressing social pressures on families.

Reducing childhood trauma exposure improves lifelong health while potentially lowering broader societal monetary costs associated with premature death and disease.

The Trauma-informed Wales Framework establishes a societal approach to understanding and responding to trauma, recognizing how past experiences shape adult needs and behavior.

Adults exposed to childhood adversity face heightened risks of mental illness, chronic physical conditions, health-harming behaviors, and poorer education and employment outcomes.

Former NIMH Director Steven Hyman noted that functional unblinding remains a clinical trial challenge because patients recognize the subjective effects of psychedelic drugs, citing FDA's 2024 rejection of Lykos Therapeutics' MDMA therapy.

Compass Pathways CEO Kabir Nath stated that COMP360 clinical trial session recordings revealed patients spent approximately 80% of session time in silence after the company deliberately separated psychotherapy from trial protocols.

Compass Pathways is engaging commercial insurers and CMS regarding reimbursement mechanisms for clinical monitoring required during COMP360 psilocybin treatment sessions.

The Department of Health and Human Services is funding early-stage clinical trials of ibogaine to treat opioid addiction and post-traumatic stress disorder through ARPA-H and NIDA.

Psychedelics should be legal for therapeutic use

The Department of Health and Human Services is prioritizing adults with post-traumatic stress disorder as one of two initial populations for federally supported ibogaine research.

The potential therapeutic benefits of ibogaine justify its severe cardiac risks

Scottish Drugs Forum Chief Executive Kirsten Horsburgh stated that the rise in drug deaths is shaped by wider factors including poverty, trauma, and housing insecurity.

COMP360 is designed to slot directly into existing clinic workflows, utilizing the same multidisciplinary staff that currently monitors Spravato patients.

Johnson & Johnson's Spravato, an inhaled esketamine treatment approved in 2019, established the clinical infrastructure that Compass Pathways plans to utilize for COMP360.

Compass Pathways established a reimbursement framework to ensure clinics are reimbursed for every hour of the six-to-eight-hour COMP360 observation period.

Among the first 60 patients treated at the Alder Hey clinic, 16 had autism, ADHD, or both, one in five had experience in the care system, and 72% had experienced childhood emotional trauma.

Compass Pathways plans a highly contained, carefully managed initial launch for COMP360 to ensure positive early patient experiences before scaling.

Interventional psychiatry clinics have built excess capacity ahead of new drug approvals, partly because Spravato requires 25 to 50 three-hour visits per year.